AI-Driven Personalized Cancer Vaccine Developed for Dog

Australian tech entrepreneur Paul Conyngham has successfully developed a personalized mRNA cancer vaccine for his eight-year-old rescue dog, Rosie, who was diagnosed with advanced mast cell cancer in 2024. After conventional treatments, including chemotherapy, yielded limited results, Conyngham turned to artificial intelligence tools, specifically ChatGPT and AlphaFold, to analyze Rosie's tumor. He sequenced the tumor's DNA, converting it from tissue to data to identify targetable mutations. This process led to the creation of a custom mRNA vaccine tailored specifically for Rosie's cancer.

Tech entrepreneur uses AI to create personalised cancer vaccine for his dogNew York PostNewsweekTech entrepreneur uses AI to build custom cancer vaccine for dogWIONPeople Magazine

Conyngham collaborated with the University of New South Wales (UNSW), particularly with Professor Páll Thordarson, director of the RNA Institute. After Conyngham provided the AI-derived genetic sequence, the UNSW team manufactured the vaccine in less than two months. The vaccine was administered to Rosie in December 2024, with significant improvements observed shortly thereafter. Conyngham reported that the treatment reduced the size of a prominent tumor on Rosie's leg by approximately 75%, enhancing her mobility and overall quality of life.

NewsweekTech entrepreneur uses AI to build custom cancer vaccine for dogTech entrepreneur uses AI to create personalised cancer vaccine for his dogPeople MagazineNew York Post

Conyngham's approach highlights the potential of AI in developing personalized medical treatments. Despite having no formal medical training, his background in machine learning and data analysis enabled him to navigate the complexities of genetic sequencing and vaccine design. The success of this project raises questions about the feasibility of similar rapid treatments for human patients, as noted by UNSW researchers. Martin Smith, director of the UNSW Ramaciotti Centre for Genomics, emphasized the implications for human medicine, suggesting that if such advancements can be made for dogs, they should be pursued for humans as well.

Tech entrepreneur uses AI to build custom cancer vaccine for dog

While the project has garnered attention for its innovative approach, it was not without challenges. Conyngham faced significant bureaucratic hurdles in obtaining ethics approval for the treatment, which took three months to finalize. Additionally, there were initial doubts from researchers about the feasibility of creating the vaccine in time to benefit Rosie. However, the collaboration ultimately proved successful, demonstrating the potential for AI to democratize medical advancements.

Tech entrepreneur uses AI to build custom cancer vaccine for dog

Conyngham and his team are currently investigating why some of Rosie's tumors did not respond to the vaccine, aiming to develop a second treatment. This ongoing research underscores the broader potential of personalized mRNA therapies, not only for cancer but potentially for other conditions, including neurological diseases.

Tech entrepreneur uses AI to create personalised cancer vaccine for his dog

• “Rose is my best mate, and she’s been with me through really tough times…when she was handed this sentence [a terminal cancer diagnosis], I felt I had to do my part for her as well.” — Paul Conyngham, Tech Entrepreneur

Newsweek

• “It raises the question, if we can do this for a dog, why aren’t we rolling this out to all humans with cancer?” — Martin Smith, Director, UNSW Ramaciotti Centre for Genomics

New York Post

• “The red tape was actually harder than the vaccine creation, and I was trying to get an Australian ethics approval to run a drug trial on Rosie,” — Paul Conyngham, Tech Entrepreneur

New York Post

This case exemplifies how AI can facilitate innovative solutions in healthcare, potentially paving the way for future breakthroughs in personalized medicine.

WION